Powered by

3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX(TM) Products in Mainland China

Mar 03, 2019 - PR Newswire

PR Newswire

3SBio Inc. ("3SBio") (HKEX: 1530) and Taiwan Liposome Company, Ltd. ("TLC") (Nasdaq: TLC, TWO: 4152) today announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC's proprietary NanoX(TM) technology platform in the therapeutic areas of oncology and severe infectious diseases. Under this alliance, TLC and 3SBio will cooperate to obtain regulatory approvals in mainland China, and TLC will utilize its commercial-scale manufacturing...